Abstract
Psychostimulants have euphoric and alerting properties that suggest their usefulness in treating depressive disorders; however, problems with tolerance and dependence with some drugs militate against their widespread therapeutic use where more acceptable licensed alternatives are available. The introduction of modafinil, a stimulant not associated with tolerance and dependence, has re-awakened interest in psychostimulants as antidepressants. The available literature, while containing somewhat inconsistent data of rather poor quality, does suggest that psychostimulants have useful antidepressant properties and are usually well tolerated. They may be useful as adjuncts to standard antidepressants in refractory depression, but have particular utility in conditions where a prompt therapeutic effect is desired and where tolerance and dependence are less of a concern. Such conditions include the treatment of depression in terminal illness and in extreme old age.
Psychostimulants, although now largely discarded as treatment options for depression, deserve careful consideration as potential therapeutic agents in specific patient subgroups.
Similar content being viewed by others
References
Connell PH. Amphetamine dependence. Proc Roy Soc Med 1968; 61(2): 170–81
Connell PH. Amphetamine psychosis. In: Maudsley Monographs no. 5. London: Oxford University Press, 1958
Janowsky DS, El-Yousef MK, Davis JM, et al. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 1973; 28: 185–91
McClellan KJ, Spencer CM. Modafinil: a review of its pharmacology and clinical efficacy in the management of narcolepsy. CNS Drugs 1998; 9(4): 311–24
Biederman J, Swanson JM, Wigal SB, et al. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry 2006; 67(5): 727–35
Mattes JA. Methylphenidate in mild depression: a double-blind controlled trial. J Clin Psychiatry 1985; 46(12): 525–7
Little KY. d-Amphetamine versus methylphenidate effects in depressed inpatients. J Clin Psychiatry 1993; 54(9): 349–55
Rickels K, Gingrich RL, McLaughlin FW, et al. Methylphenidate in mildly depressed outpatients. Clin Pharmacol Ther 1972; 13(4): 595–601
O’Donnell M. Dexamphetamine compared with an inactive placebo in depression. Practitioner 1964; 192: 151–4
Robin AA, Wiseberg S. A controlled trial of methylphenidate (ritalin) in the treatment of depressive states. J Neurol Neurosurg Psychiatry 1958; 21: 55–7
Rickels K, Gordon PE, Gansman DH, et al. Pemoline and methylphenidate in mildly depressed outpatients. Clin Pharmacol Ther 1970; 11(5): 698–710
Hare EH, Dominian J, Sharpe L. Phenelzine and dexamphetamine in depressive illness; a comparative trial. BMJ 1962; 5270: 9–12
Rudolf GDEM. The treatment of depression with desoxyephedrine (methedrine). J Ment Sci 1949; 95: 920–9
Wilbur DL, MacLean AR, Allen EV. Clinical observation on the effect of benzedrine sulphate: a study of patients with states of chronic exhaustion, depression and psychoneurosis. JAMA 1937; 109(8): 549–54
Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61(6): 436–40
Kaplitz SE. Withdrawn, apathetic geriatric patients responsive to methylphenidate. J Am Geriatr Soc 1975; 23(6): 271–6
DeBattista C, Lembke A, Solvason HB, et al. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol 2004; 24(1): 87–90
Gwirtsman HE, Szuba MP, Toren L, et al. The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. Psychopharmacol Bull 1994; 30(2): 157–64
Rasmussen NA, Schroder P, Olsen LR, et al. Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-reported symptoms covered by the major depression inventory (MDI) and the symptom checklist (SCL-92). Nord J Psychiatry 2005; 59(3): 173–8
Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005; 66(1): 85–93
DeBattista C, Doghramji K, Menza MA, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64(9): 1057–64
Schwartz TL, Azhar N, Cole K, et al. An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. J Clin Psychiatry 2004; 65(9): 1223–7
Fawcett J, Kravitz HM, Zajecka JM, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment refractory depression. J Clin Psychopharmacol 1991; 11(2): 127–32
Postolache TT, Rosenthal RN, Hellerstein DJ, et al. Early augmentation of sertraline with methylphenidate. J Clin Psychiatry 1999; 60(2): 123–4
Markovitz PJ, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy. J Clin Psychopharmacol 2003; 23(2): 207–9
Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manage 1998; 16(3): 193–8
Homsi J, Nelson KA, Sarhill N, et al. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care 2001; 18(6): 403–7
Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 1996; 37(1): 57–62
Fernandez F, Adams F, Holmes VF, et al. Methylphenidate for depressive disorders in cancer patients. Psychosomatics 1987; 28(9): 455–61
Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood and function of brain tumor patients. J Clin Oncol 1998; 16(7): 2522–7
Grade C, Redford B, Chrostowski J, et al. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil 1998; 79: 1047–50
Lazarus LW, Winemiller DR, Lingam VR, et al. Efficacy and side effects of methylphenidate for poststroke depression. J Clin Psychiatry 1992; 53(12): 447–9
Masand P, Pickett P, Murray GB. Psychostimulants in post-stroke depression. J Neuropsychiatry Clin Neurosci 1991; 3(1): 23–7
Lingam VR, Lazarus LW, Groves L, et al. Methylphenidate in treating poststroke depression. J Clin Psychiatry 1988; 49(4): 151–3
Wagner GJ, Rabkin R, Rabkin JG. Dexamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res 1997; 42(4): 407–11
Reynolds III CF, Frank E, Dew MA, et al. Treatment of 70 (+)-year-olds with recurrent major depression: excellent short-term but brittle long-term response. Am J Geriatr Psychiatry 1999; 7(1): 64–9
Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25(6): 1171–80
Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life: consensus statement update. JAMA 1997; 278(14): 1186–90
Geerlings SW, Beekman AT, Deeg DJ, et al. The longitudinal effect of depression on functional limitations and disability in older adults: an eight-wave prospective community-based study. Psychol Med 2001; 31(8): 1361–71
Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995; 152(6): 929–31
Lavretsky H, Kim MD, Kumar A, et al. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry 2003; 64(12): 1410–4
Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry 2001; 9(3): 298–303
Jacobson A. The use of ritalin in psychotherapy of depression of the aged. Psychiatr Q 1958; 32: 474–83
Pickett P, Masand P, Murray GB. Psychostimulant treatment of geriatric depressive disorders secondary to medical illness. J Geriatr Psychiatry Neurol 1990; 3(3): 146–51
Woods SW, Tesar GE, Murray GB, et al. Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry 1986; 47(1): 12–5
Masand P, Pickett P, Murray GB. Psychostimulants for secondary depression in medical illness. Psychosomatics 1991; 32(2): 203–8
Rosenberg PB, Ahmed I, Hurwitz S. Methylphenidate in depressed medically ill patients. J Clin Psychiatry 1991; 52(6): 263–7
Rothenhausler HB, Ehrentraut S, Degenfeld GV, et al. Treatment of depression with methylphenidate in patients difficult to wean from mechanical ventilation in the intensive care unit. J Clin Psychiatry 2000; 61(10): 750–5
Landman ME, Preisig R, Perlman M. A practical mood stimulant. J Med Soc N J 1958; 55(2): 55–8
Hornig-Rohan M, Amsterdam JD. Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 585–9
Lundt L. Modafinil treatment in patients with measonal affective disorder/ winter depression: an open-label pilot study. J Affect Disord 2004; 81: 173–8
El-Mallakh RS. An open study of methylphenidate in bipolar depression. Bipolar Disord 2000; 2: 56–9
Jonas AD. The adjunctive use of an intravenous amphetamine in psychotherapy. J Nerv Ment Dis 1954; 119: 135–47
Linet LS. Treatment refractory depression with a combination of fluoxetine and dexamphetamine. Am J Psychiatry 1989; 146(6): 803–4
Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000; 61(5): 378–81
Xiong GL, Christopher EJ, Goebel J. Modafinil as an alternative to methylphenidate as augmentation for depression treatment. Psychosomatics 2005; 46(6): 578–9
Schwartz TL, Leso L, Beale M, et al. Modafinil in the treatment of depression with severe comorbid medical illness. Psychosomatics 2002; 43(3): 336–7
Ward NG, Lampe TH. A trial of dextroamphetamine in patients with involutional agitated depression. J Clin Psychiatry 1982; 43(1): 35–6
Kaufman KR, Menza MA, Fitzsimmons A. Modafinil monotherapy in depression. Eur Psychiatry 2002; 17(3): 167–9
Stiebel VG. Methylphenidate plasma levels in depressed patients with renal failure. Psychosomatics 1994; 35(5): 498–500
Holmes TF, Sabaawi M, Fragala MR. Psychostimulant suppository treatment for depression in the gravely ill. J Clin Psychiatry 1994; 55(6): 265–6
Kaufmann MW, Cassem NH, Murray GB, et al. Use of psychostimulants in medically ill patients with neurological disease and major depression. Can J Psychiatry 1984; 29(1): 46–9
Kaufmann MW, Cassem NH, Murray GB, et al. The use of methylphenidate in depressed patients after cardiac surgery. J Clin Psychiatry 1984; 45(2): 82–4
Kaufmann MW, Murray GB. The use of d-amphetamine in medically ill depressed patients. J Clin Psychiatry 1982; 43(11): 463–4
Kaufmann MW, Murray GB, Cassem NH. Use of psychostimulants in medically ill depressed patients. Psychosomatics 1982; 23(8): 817–9
Block SD. Assessing and managing depression in the terminally ill patient. Ann Intern Med 2000; 132: 209–18
Sugden SG, Bourgeois JA. Modafinil monotherapy in post-stroke depression. Psychosomatics 2004; 45(1): 80–1
Homsi J, Walsh D, Nelson KA, et al. Methylphenidate for depression in hospice practice. Am J Hosp Palliat Care 2000; 17(6): 393–8
Sarhill N, Walsh D, Nelson KA, et al. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 2001; 18(3): 187–92
Burns MM, Eisendrath SJ. Dextroamphetamine treatment for depression in terminally ill patients. Psychosomatics 1994; 35(1): 80–3
Frye CB. Methylphenidate for depression in the elderly, medically ill patient. Am J Health Syst Pharm 1997; 54(21): 2510–1
Gurian B, Rosowsky E. Low-dose methylphenidate in the very old. J Geriatr Psychiatry Neurol 1990; 3(3): 152–4
Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 2000; 14(1): 3–20
Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry 2003; 64(2): 123–33
Summary of product characteristics (SPC) for Provigil® 100 and 200mg tablets (modafinil) [online]. Available from URL: http://www.medicines.org.uk [Accessed 2006 Dec 27]
Summary of product characteristics (SPC) for Dexedrine® 5mg (dexamphetamine) [online]. Available from URL: http://www.medicines.org.uk [Accessed 2006 Dec 27]
Summary of product characteristics (SPC) for Equasym® 5, 10 and 20mg tablets (methylphenidate) [online]. Available from URL: http://www.medicines.org.uk [Accessed 2006 Dec 27]
Micromedex® healthcare series. Modafinil Drugdex® evaluation [online]. Available from URL: http://healthcare.micromedex.com [Accessed 2006 Feb 7]
Micromedex® healthcare series. Dexamphetmaine Drugdex® evaluation [online]. Available from URL: http://healthcare.micromedex.com [Accessed 2006 Feb 7]
Micromedex® healthcare series. Methylphenidate Drugdex® evaluation [online]. Available from URL: http://healthcare.micromedex.com [Accessed 2006 Feb 7]
Markowitz PJ, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy. J Clin Psychopharmacol 2003; 23(2): 207–8
Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2006; 163(7): 1149–52
Koehler-Troy C, Strober M, Malenbaum R. Methylphenidate-induced mania in a prepubertal child. J Clin Psychiatry 1986; 47(11): 566–7
Vorspan F, Warot D, Consoli A, et al. Mania in a boy treated with modafinil for narcolepsy. Am J Psychiatry 2005; 162(4): 813–4
Food and Drug Administration. Drug Safety and Risk Management Advisory Committee meeting, 9–10 February 2006: table of contents [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4202_00_TOC.htm) [Accessed 2006 Apr 18]
Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354(14): 1445–8
Bennett IL, Walker WE. Cardiac arrhythmias following the use of large doses of central nervous system stimulants. Am Heart J 1952; 44: 428
Anders T, Sharfstein S. ADHD drugs and cardiovascular risk [letter]. N Engl J Med 2006; 354(21): 2296–8
Acknowledgements
No sources of funding were used to assist in the preparation of this review. Dr Taylor has acted as a consultant to Servier Laboratories and Lundbeck Plc; received honoraria from Eli Lilly & Co., Lundbeck Plc and Wyeth; and received grants from Lundbeck Plc. Ms Orr has no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Orr, K., Taylor, D. Psychostimulants in the Treatment of Depression. CNS Drugs 21, 239–257 (2007). https://doi.org/10.2165/00023210-200721030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200721030-00004